Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management Cassinat B; Chomienne COncogene 2001[Oct]; 20 (49): 7154-60In recent years, discovery of the in vitro and in vivo differentiation of APL blasts by all-trans retinoic acid (ATRA) has modified the therapeutic approach of APL and lead to important advances in understanding the biology of APL. Since it became apparent that differentiation therapy of APL with ATRA was indeed a true model of targetted therapy, evidencing the molecular targets of retinoic acid efficacy became crucial. These molecular targets are closely related to the biological features of APL cells, some of which are well-known and have contributed to the morphological and cytogenetic definition of the leukemia, others have just been defined or re-discovered in the light of a better understanding of molecular controls of cell growth and differentiation. The aims of characterizing the biological features of APL cells should allow a better management of APL therapy and the identification of potential markers for differentiation therapies in other leukemias or solid tumors.|*Hematopoiesis[MESH]|Biomarkers, Tumor[MESH]|Cell Differentiation/drug effects[MESH]|Cell Division/drug effects[MESH]|Disease Management[MESH]|Granulocytes/*cytology[MESH]|Humans[MESH]|Leukemia, Promyelocytic, Acute/drug therapy/etiology/*metabolism/*pathology[MESH]|Signal Transduction/drug effects[MESH]|Tretinoin/metabolism/therapeutic use[MESH] |